The role of antiplatelet therapy in the management of acute coronary syndromes

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 541-556

  Volturo, Gregory A ^a   Mazzola, Jennifer L ^b   Przylenk, Karin ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Abciximab; Acute; Antiplatelet; Aspirin; Clopidogrel; Eptifibatide; Glycoprotein (GP) IIb IIIa receptor; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; COUMARIN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; PYRIDINE DERIVATIVE; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL PAIN; BLEEDING TENDENCY; BONE MARROW TOXICITY; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSPEPSIA; ENZYME DEFECT; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; LIVER FUNCTION TEST; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRURITUS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; URTICARIA; VOMITING;

ACUTE DISEASE; ADMINISTRATION, ORAL; CLINICAL TRIALS; HUMANS; INFUSIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 19444374327     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.541     Document Type: Review

References (96)

1. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308(6921):81-106.
2. The Risc Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet (1990) 336(8719):827-830.
3. LEWIS HD, Jr., DAVIS JW, ARCHIBALD DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1983) 309(7):396-403.
4. The Epilog Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. (1997) 336(24):1689-1696.
5. The Capture Study Invesitagors: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429-1435.
6. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. (1998) 338(21):1498-1505.
7. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. (1998) 338(21):1488-1497.
8. The Pursuit Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. (1998) 339(7):436-443.
9. The Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) Investigators: Effects of platelet glycoptotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation (1997) 96(5):1445-1453.
10. The Epistent Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet (1998) 352(9122):87-92.
11. BERTRAND ME, RUPPRECHT HJ, URBAN P, GERSHLICK AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000) 102(6):624-629.
12. YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOGNONI G, FOX KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502.
13. MICHELSON AD: How platelets work: platelet function and dysfunction. J. Thromb. Thrombolysis (2003) 16(1-2):7-12.
14. BECKER RC: Platelet surface physiology and its importance in pharmacotherapy design and development: the adenosine diphosphate receptor antagonists. J. Thromb. Thrombolysis (2000) 10(1):35-53.
15. BATES SM, WEITZ JI: Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin. Cardiovasc. Res. (1999) 41(2):418-432.
16. THEROUX P, FUSTER V: Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation (1998) 97(12):1195-1206.
17. PATRONO C: Aspirin as an antiplatelet drug. N. Engl. J. Med. (1994) 330(18):1287-1294.
18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J. Am. Coll. Cardiol. (1988) 12(6 Suppl. A):3A-13A.
19. TAYLOR DW, BARNETT HJ, HAYNES RB et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet (1999) 353(9171):2179-2184.
20. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324(7329):71-86.
21. VAN HECKEN A, JULIANO ML, DEPRE M et al.: Effects of enteric-coated, low-dose aspirin on parameters of platelet function. Aliment. Pharmacol. Ther. (2002) 16(9):1683-1688.
22. VOLTURO GA, AGHABABIAN RV: Facilitating optimal care of acute coronary, cerebrovascular and peripheral vascular syndromes in the emergency department: the role of oral antiplate therapy. J. Thromb. Thrombolysis (2004) 17(1):29-34.
23. GUM PA, KOTTKE-MARCHANT K, WELSH PA, WHITE J, TOPOL EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. (2003) 41(6):961-965.
24. CHEN WH, LEE PY, NG W, TSE HF, LAU CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. (2004) 43(6):1122-1126.
25. ANTMAN EM, COHEN M, BERNINK PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 284(7):835-842.
26. ALEXANDER JH, HARRINGTON RA, TUTTLE RH et al.: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am. J. Cardiol. (1999) 83(8):1147-1151.
27. BHATT DL: Aspirin resistance: more than just a laboratory curiosity. J. Am. Coll. Cardiol. (2004) 43(6):1127-1129.
28. FITZGERALD GA: Dipyridamole. N. Engl. J. Med. (1987) 316(20):1247-1257.
29. MULLER TH, SU CA, WEISENBERGER H, BRICKL R, NEHMIZ G, EISERT WG: Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br. J. Clin. Pharmacol. (1990) 30(2):179-186.
30. DIENER HC, CUNHA L, FORBES C, SIVENIUS J, SMETS P, LOWENTHAL A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. (1996) 143(1-2):1-13.
31. PATRONO C, COLLER B, DALEN JE et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (2001) 119(Suppl. 1):39S-63S.
32. AMBROSE JA: Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different? J. Am. Coll. Cardiol. (1992) 19(7):1653-1658.
33. STEINHUBL SR, BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288(19):2411-2420.
34. SCHOMIG A, NEUMANN FJ, KASTRATI A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. (1996) 334(17):1084-1089.
35. BERTRAND ME, LEGRAND V, BOLAND J et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 98(16):1597-1603.
36. MUELLER C, ROSKAMM H, NEUMANN FJ et al.: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J. Am. Coll. Cardiol. (2003) 41(6):969-973.
37. BHATT DL, BERTRAND ME, BERGER PB et al.: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J. Am. Coll. Cardiol. (2002) 39(1):9-14.
38. SAVI P, NURDEN P, NURDEN AT: Clopidogrel: A review of its mechanism of action. Platelets (1998) 9:251-255.
39. CAPRIE SC: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329-1339.
40. CADROY Y, BOSSAVY JP, THALAMAS C, SAGNARD L, SAKARIASSEN K, BONEU B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation (2000) 101(24):2823-2828.
41. GENT M: Benefit of Clodogrel in patients with coronary disease. Circulation (1997) 96:I467 (abstract).
42. HARKER LA, MARZEC UM, KELLY AB et al.: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation (1998) 98(22):2461-2469.
43. MAKKAR RR, EIGLER NL, KAUL S et al.: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur. Heart J. (1998) 19(10):1538-1546.
44. BUDAJ A, YUSUF S, MEHTA SR et al.: Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 106(13):1622-1626.
45. HIRSH J, BHATT DL: Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch. Intern. Med. (2004) 164(19):2106-2110.
46. MEHTA SR, YUSUF S, PETERS RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358(9281):527-533.
47. BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. (2002) 40(7):1366-1374.
48. GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107(23):2908-2913.
49. MATETZKY S, SHENKMAN B, GUETTA V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109(25):3171-3175.
50. SEREBRUANY VL, STEINHUBL SR, BERGER PB, MALININ AI, BHATT DL, TOPOL EJ: Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. (2005) 45(2):246-251.
51. BONEU B, DESTELLE G: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb. Haemost. (1996) 76(6):939-943.
52. JARVIS B, SIMPSON K: Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs (2000) 60(2):347-377.
53. SAVCIC M, HAUERT J, BACHMANN F, WYLD PJ, GEUDELIN B, CARIOU R: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. (1999) 25(Suppl. 2):15-19.
54. CHEN L, BRACEY AW, RADOVANCEVIC R et al.: Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. (2004) 128(3):425-431.
55. CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103(2):201-206.
56. KLEIMAN NS, OHMAN EM, CALIFF RM et al.: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J. Am. Coll. Cardiol. (1993) 22(2):381-389.
57. MOSER M, BERTRAM U, PETER K, BODE C, RUEF J: Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J. Cardiovasc. Pharmacol. (2003) 41(4):586-592.
58. WHITE HD: Unmet therapeutic needs in the management of acute ischemia. Am. J. Cardiol. (1997) 80(4A):2B-10B.
59. ELLIS SG, TCHENG JE, NAVETTA FI et al.: Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron. Artery Dis. (1993) 4(2):167-175.
60. MASCELLI MA, LANCE ET, DAMARAJU L, WAGNER CL, WEISMAN HF, JORDAN RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998) 97(17):1680-1688.
61. TCHENG JE, ELLIS SG, GEORGE BS et al.: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 90(4):1757-1764.
62. MADAN M, BERKOWITZ SD, TCHENG JE: Glycoprotein IIb/IIIa integrin blockade. Circulation (1998) 98(23):2629-2635.
63. KNIGHT DM, WAGNER C, JORDAN R et al.: The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. (1995) 32(16):1271-1281.
64. TCHENG JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol. (1996) 78(3A):35-40.
65. TAM SH, SASSOLI PM, JORDAN RE, NAKADA MT: Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation (1998) 98(11):1085-1091.
66. COLLER BS: Potential non-glycoprotein IIb/IIIa effects of abciximab. Am. Heart J. (1999) 138(1 Pt 2):S1-S5.
67. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IlIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. (1994) 330(14):956-961.
68. SIMOONS ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357(9272):1915-1924.
69. SCARBOROUGH RM, Rose JW, Naughton MA et al.: Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. (1993) 268(2):1058-1065.
70. KLEIMAN NS: Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am. Heart J. (1999) 138(4 Pt 2):263-275.
71. IMPACT-II: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (1997) 349(9063):1422-1428.
72. The Esprit Investigator: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356(9247):2037-2044.
73. TCHENG JE, TALLEY JD, O'SHEA JC et al.: Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am. J. Cardiol. (2001) 88(10):1097-1102.
74. TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. (2001) 344(25):1888-1894.
75. OHMAN EM, KLEIMAN NS, GACIOCH G et al.: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation (1997) 95(4):846-854.
76. TOPOL EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet (2001) 357(9272):1905-1914.
77. The Assent Investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358(9282):605-613.
78. LINCOFF AM, CALIFF RM, VAN DE WERF F et al.: Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA (2002) 288(17):2130-2135.
79. The Paradigm Investigators: Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J. Am. Coll. Cardiol. (1998) 32(7):2003-2010.
80. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group: Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation (2000) 101(24):2788-2794.
81. ANTMAN EM, GIUGLIANO RP, GIBSON CM et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 99(21):2720-2732.
82. DALBY M, MONTALESCOT G, BAL DIT SOLLIER C et al.: Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol. (2004) 43(2):162-168.
83. ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E et al.: High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability Eur. Heart J. (2004) 25(21):1903-1910.
84. KASTRATI A, VON BECKERATH N, JOOST A, POGATSA-MURRAY G, GORCHAKOVA O, SCHOMIG A: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation (2004) 110(14):1916-1919.
85. DE LA CRUZ JP, ARREBOLA MM, VILLALOBOS MA et al.: Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur. J. Pharmacol. (2004) 484(1):19-27.
86. BHATT DL, TOPOL EJ: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. (2004) 148(2):263-268.
87. KASTRATI A, MEHILLI J, SCHUHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. (2004) 50(3):232-238.
88. SABATINE MS, CANNON CP, GIBSON CM et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. (2005) 352(12):1179-1189.
89. RODERICK PJ, WILKES HC, MEADE TW: The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol. (1993) 35(3):219-226.
90. CHAN FK, CHING JY, HUNG LC et al.: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. (2005) 352(3):238-244.
91. CURTIN R, FOX D, FITZGERAL D: In: Clopidogrel and Ticlopidine. Michelson AD, (Ed.) Platelets. San Diego: Academic Press; 2002.
92. LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107(1):32-37.
93. SEREBRUANY VL, MIDEI MG, MALININ AI et al.: Absence of interaction between atorvastarin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. (2004) 164(18):2051-2057.
94. SAW J, STEINHUBL SR, BERGER PB et al.: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 108(8):921-924.
95. BERKOWITZ SD, SANE DC, SIGMON KN et al.: Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J. Am. Coll. Cardiol. (1998) 32(2):311-319.
96. TCHENG JE, KEREIAKES DJ, LINCOFF AM et al.: Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 104(8):870-875.